SCREENING ON PATIENTS WITH ALLERGIC BRONCHOPULMONARY DISEASES

Aigul Medetova*, **, Galiya Abdulina*, Berik Kouchebekov*, Zhanbolat  Sailau*, Dan Moraru****, Sorina Anamaria Pestrea*****,  Antonella Chesca***, ****

*Karaganda Medical University, Kazakhstan - **Karaganda Clinical Diagnostic Laboratory OLYMP, Kazakhstan - ***Transilvania University of Brasov, Romania - ****Clinical Hospital of Pneumophtysiology Braşov, Romania - ****Clinical Hospital of Psychiatry and Neurology Brasov, Romania

Objective: Half of the human population develops allergic symptoms to fungi during their lifetime. Knowing this fact, in the present study the screening for the presence of a specific Aspergillus IgG in patients with chronic bronchopulmonary and allergic diseases was investigated.

The aim of the study: Is to show the prevalence of aspergillosis in patients with allergic, bronchopulmonary pathology in various age groups in Karaganda of RK.

Materials and Methods: We examined 1147 patients with bronchopulmonary infections, allergic diseases. Aspergillus IgG were determined by ELISA using a set of reagents Vector-BEST (Russia). Statistical Analysis was performed using the STATISTICA-6 package.

Results: 32.6% of patients with bronchopulmonary, allergic diseases have a positive test for Aspergillus-Specific IgG immunoglobulins. The most often (43,28%) positive test was detected in children of 4-10 years old. These are children of primary school and preschool institutions. High percentages (40,72%) of positive tests were also noted in 0-3 age group. With increasing age, the number of positive results decreased. Analysis of patients with high values of antibodies also showed significantly high rates in children of 4-10 years (10,92%) compared with age groups 0-3 (5,39%), 21-50 3,8% and >50 years (4,17%) at p=0,038; 0,001 and 0,01 respectively.The most vulnerable age group is children 4-10 years old

Conclusion: Every third patient suffering from allergic or bronchopulmonary diseases has a positive test for the specific Aspergillus IgG. The most vulnerable age group is children 4-10 years old.